|Articles|April 1, 2004

April 2004
Volume 10
Issue 4

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Author(s)Robert Valuck, PhD, RPH. Author Reply by Emily R. Cox, PhD, Brenda Motheral, PhD, Doug Mager, BS

Articles in this issue

almost 22 years ago

Article

Improving Cancer Screening Adherence: Using the "Teachable Moment" as a Delivery Setting for Educational Interventions

almost 22 years ago

Article

Population-Based Hepatitis C Surveillance and Treatment in a National Managed Care Organization

almost 22 years ago

Article

Malpractice Prevention, Patient Safety, and Quality of Care: A Critical Linkage

almost 22 years ago

Article

Comparing Breast Cancer Case Identification Using HMO Computerized Diagnostic Data and SEER Data

almost 22 years ago

Article

Health Plan Policies and Programs for Colorectal Cancer Screening: A National Profile

almost 22 years ago

Article

Primary Care Practice and Facility Quality Orientation: Influence on Breast and Cervical Cancer Screening Rates

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

Prior Authorization Ranked Top Barrier to Health Care Access After Cost

FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film

Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024

Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD

Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM